Shire Health bags BMS Sprycel job

Bristol-Myers Squibb is using Shire Health London to advise on UK comms for Sprycel, its pill for chronic myeloid leukaemia (CML).

The drug was approved by the US Food and Drug Administration this summer, and was recommended for approval in the EU two months ago.

Sprycel is able to treat CML in patients who are resistant or intolerant to Novartis's established leukaemia pill Gleevec.

The appointment extends the links between Bristol-Myers Squibb and Shire Health London: BMS handed the agency a UK brief for schizophrenia drug Abilify earlier this year (PRWeek, 4 August).

SEPERATELY... Bristol-Myers Squibb has also been using London-based start-up Just Health PR on a UK project basis to support its interests in rheumatoid arthritis, the disease area of its drug Orencia (abatacept).

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in